Freeline Therapeutics to Host Full Year 2022 Financial Results Call
28 Marzo 2023 - 5:00AM
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today
announced that it will host a live conference call and webcast at
8:00 a.m. ET on Tuesday, April 4, 2023 to report its full year 2022
financial results and provide a corporate update.
To access the conference call, participants may register here.
While not required, it is recommended that participants join the
call 10 minutes prior to the scheduled start. A live webcast of the
call will also be available on the Investors section of Freeline’s
website at www.freeline.life. An archived replay of the webcast be
available for approximately 90 days following the call.
About Freeline TherapeuticsFreeline is a
clinical-stage biotechnology company developing transformative
adeno-associated virus (AAV) vector-mediated gene therapies. The
company is dedicated to improving patient lives through innovative,
one-time treatments for chronic debilitating diseases. Freeline
uses its proprietary, rationally designed AAV vector and capsid
(AAVS3), along with novel promoters and transgenes, to deliver a
functional copy of a therapeutic gene into human liver cells,
thereby expressing a persistent functional level of the missing or
dysfunctional protein into the patient’s bloodstream. The company
is advancing clinical programs in Fabry disease and Gaucher disease
Type 1. Freeline is headquartered in the UK and has operations in
the United States. For more information about the company, visit
www.freeline.life or connect with Freeline on LinkedIn and
Twitter.
Media and Investor Contact:Naomi
Aokinaomi.aoki@freeline.lifeSenior Vice President, Head of Investor
Relations & Communications+ 1 617 283 4298
Freeline Therapeutics (NASDAQ:FRLN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Freeline Therapeutics (NASDAQ:FRLN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024